Skip to main content

AN2 Therapeutics, Inc.

corporate_fare Company Profile

AN2 Therapeutics, Inc.

ANTX·NASDAQ·Life Sciences·CIK 0001880438

AN2 Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops new small-molecule therapeutics using its boron chemistry platform. The company's development pipeline includes programs in hematologic diseases, infectious diseases, and oncology. AN2 Therapeutics has three Phase 2 studies anticipated to begin in 2026, two preclinical candidates, and advanced research programs targeting oncology, bone disorders, and infectious diseases. One key product in development is epetraborole, which is being expanded into a Phase 2 proof-of-concept clinical study for adults with phlebotomy-dependent polycythemia vera (PV). PV is a blood cancer where the bone marrow overproduces red blood cells, increasing hematocrit and potentially leading to serious complications like arterial and venous thromboembolic events. Approximately 155,000 people in the U.S. are estimated to be affected by PV. AN2 Therapeutics plans to initiate the Phase 2 trial for epetraborole in India in the third quarter of 2026. This study is expected to include an open-label sentinel cohort, an open-label dose optimization cohort (Part 1), a double-blind, randomized, placebo-controlled cohort (Part 2), and an optional open-label extension cohort (Part 3).

AN2 Therapeutics, Inc. (NASDAQ:ANTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for ANTX at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • AN2 Therapeutics Appoints New Principal Accounting Officer, Reduces CFO Compensation Amid Cost-Savings

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$35.17M
Diluted EPS
-$1.16
Op. Cash Flow
-$29.83M
Operating Income
-$38.11M
Cash & Equivalents
$19.94M
Debt / Equity
0.00×
Shares Outstanding
27.41M sh
Source: 10-K · filed 2026-03-17 · accession 0001193125-26-110693
$5.08
52-week range · as of 2026-11-09 $1 – $7.19
Market cap
$192.75M
Volume
332.7K (1.1× avg)
3-mo avg 315.5K
Live data · 2026-11-22 12:46 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ANTX - Filings & News (Page 2)

ANTX
Jan 29, 2026, 4:45 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.13
Real-time Price: $5.08 info
Change: +$3.95 (+350%) info
Market Cap: $192.754M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets